{"cells":[{"cell_type":"code","execution_count":1,"metadata":{"execution":{"iopub.execute_input":"2023-04-14T22:59:45.622634Z","iopub.status.busy":"2023-04-14T22:59:45.622217Z","iopub.status.idle":"2023-04-14T23:00:02.416542Z","shell.execute_reply":"2023-04-14T23:00:02.414984Z","shell.execute_reply.started":"2023-04-14T22:59:45.622599Z"},"trusted":true},"outputs":[{"name":"stdout","output_type":"stream","text":["\u001b[38;5;2m✔ Imported 777 annotations to 'ner_combine' (session\n","2023-04-23_13-41-06) in database SQLite\u001b[0m\n","Found and keeping existing \"answer\" in 777 examples\n"]}],"source":["!prodigy db-in ner_combine ner_C07K_combine.jsonl"]},{"cell_type":"code","execution_count":4,"metadata":{},"outputs":[{"name":"stdout","output_type":"stream","text":["\u001b[38;5;4mℹ Using CPU\u001b[0m\n","\u001b[38;5;4mℹ To switch to GPU 0, use the option: --gpu-id 0\u001b[0m\n","\u001b[1m\n","========================= Generating Prodigy config =========================\u001b[0m\n","\u001b[38;5;4mℹ Auto-generating config with spaCy\u001b[0m\n","\u001b[38;5;4mℹ Using config from base model\u001b[0m\n","\u001b[38;5;2m✔ Generated training config\u001b[0m\n","\u001b[1m\n","=========================== Initializing pipeline ===========================\u001b[0m\n","[2023-04-23 13:42:16,025] [INFO] Set up nlp object from config\n","Components: ner\n","Merging training and evaluation data for 1 components\n","  - [ner] Training: 466 | Evaluation: 112 (20% split)\n","Training: 192 | Evaluation: 44\n","Labels: ner (4)\n","[2023-04-23 13:42:16,360] [INFO] Pipeline: ['tok2vec', 'tagger', 'parser', 'attribute_ruler', 'lemmatizer', 'ner']\n","[2023-04-23 13:42:16,360] [INFO] Resuming training for: ['ner', 'tok2vec']\n","[2023-04-23 13:42:16,366] [INFO] Created vocabulary\n","[2023-04-23 13:42:16,367] [INFO] Finished initializing nlp object\n","[2023-04-23 13:42:16,367] [INFO] Initialized pipeline components: []\n","\u001b[38;5;2m✔ Initialized pipeline\u001b[0m\n","\u001b[1m\n","============================= Training pipeline =============================\u001b[0m\n","Components: ner\n","Merging training and evaluation data for 1 components\n","  - [ner] Training: 466 | Evaluation: 112 (20% split)\n","Training: 192 | Evaluation: 44\n","Labels: ner (4)\n","\u001b[38;5;4mℹ Pipeline: ['tok2vec', 'tagger', 'parser', 'attribute_ruler',\n","'lemmatizer', 'ner']\u001b[0m\n","\u001b[38;5;4mℹ Frozen components: ['tagger', 'parser', 'attribute_ruler',\n","'lemmatizer']\u001b[0m\n","\u001b[38;5;4mℹ Initial learn rate: 0.001\u001b[0m\n","E    #       LOSS TOK2VEC  LOSS NER  ENTS_F  ENTS_P  ENTS_R  SPEED   SCORE \n","---  ------  ------------  --------  ------  ------  ------  ------  ------\n","  0       0          0.00     48.72    0.00    0.00    0.00  3948.15    0.00\n","  7    1000          0.00   9862.81   45.03   45.98   44.12  4065.44    0.45\n"," 19    2000          0.00   5614.13   45.56   45.90   45.22  3905.94    0.46\n","\u001b[38;5;2m✔ Saved pipeline to output directory\u001b[0m\n","NER_model/model-last\n"]}],"source":["!prodigy train NER_model --ner ner_combine --training.max_steps=2000 --training.optimizer.learn_rate=0.001 --base-model=en_core_web_sm"]},{"cell_type":"code","execution_count":7,"metadata":{},"outputs":[{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">A method of preparing an \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    antibody suitable\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," for use in a canine is provided. Also provided are caninised antibodies which specifically bind to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine neuronal growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",") and neutralise the ability of canine NGF to bind to the p75 or \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    TrkA canine NGF receptor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",". The invention extends to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    nucleic acids\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Medication</span>\n","</mark>\n"," encoding same and to methods of treating pain and arthritis in a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine using said antibodies\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," and/or \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    nucleic acids\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Medication</span>\n","</mark>\n",".</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"name":"stderr","output_type":"stream","text":["/Users/ktgiahieu/miniconda3/lib/python3.10/site-packages/spacy/displacy/__init__.py:211: UserWarning: [W006] No entities to visualize found in Doc object. If this is surprising to you, make sure the Doc was processed using a model that supports named entity recognition, and check the `doc.ents` property manually if necessary.\n","  warnings.warn(Warnings.W006)\n"]},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">_____d:</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Field of the Invention</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The present invention relates to antibodies, and fragments thereof, which act as antagonists of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine nerve growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",". The invention extends to methods of preparing same and to the therapeutic use of these antibodies and fragments in treating conditions associated with \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    nerve growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," such as \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    pain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",", pain related disorders and conditions which result in the occurrence of chronic pain in canines.</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background to the Invention</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Nerve growth factor\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",") is a naturally occurring \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    secreted protein\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," which consists of an alpha, beta and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    gamma polypeptide chain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",". NGF is a member of the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    neurotrophin family\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," and is implicated in a number of different roles. NGF promotes survival and differentiation of sensory and sympathetic neurons and signals via two membrane bound receptors, \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    p75\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",", a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    low affinity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," NGF receptor and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    TrkA\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",", a transmembrane tyrosine kinase and a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    high affinity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n"," NGF receptor. The binding of NGF to TrkA or p75 results in an upregulation of neuropeptides in \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    sensory neurons\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",".</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The use of NGF antagonists to treat pain and pain sensitivity in humans has been described (Cattaneo A., Curr. Op. Mol. Ther. 2010 12(1):94-106). For example, \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    International Patent\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n"," Application No. WO 2006/131951 describes a humanised form of the rat alphaD11 (α11, aD11) \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    monoclonal antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",". The \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    αD11 antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," has \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding specificity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," to mouse \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",", but is also known to bind to human and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    rat forms\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," of NGF. Humanisation of the αD11 rat derived \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    monoclonal antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," is required prior to administration to humans in order to minimise the production of neutralising antibodies which result from a human \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    anti-mouse antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    HAMA\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",") response being mounted against rodent derived antibodies. Furthermore, the replacement of mouse \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    constant domains\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," with human constant domains allows downstream effector functions to be selected for.</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Pain management in canines is currently provided through administration of analgesic drugs of several classes, including local and general anaesthetics, opioid analgesics, α2 agonists, \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    non-steroidal anti-inflammatory drugs\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," (\n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NSAIDs\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",") and \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    steroids\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",". Each of these needs to be administered frequently and also has limitations in efficacy and safety. There is accordingly a need for an infrequently dosed, \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    long lasting\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n"," and efficacious form of pain relief for canines suffering from \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    chronic pain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",", such as those with \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    cancer pain\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," or \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    arthritis\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",".</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">While NGF is expressed in canine tissues and the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF molecule\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," has been characterised (Eisele I. Wood IS. \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    German AJ\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",". \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Hunter L. Trayhurn P.\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n","&quot; \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Adipokine gene expression\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n"," in dog adipose tissues and dog white adipocytes differentiated in primary culture&quot; \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    Hormone &amp; Metabolic Research\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n",". 37(8):474-81, 2005 Genbank XP_540250), no antagonist to canine \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Detailed_description</span>\n","</mark>\n"," has been described, nor has the use of blocking NGF mediated signalling in canines to prevent or alleviate pain. The use in canines of known antibodies which act as \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    anti-NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," antagonists in other species would not be feasible due to the production of neutralising antibodies. Furthermore, the production of a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    chimeric antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," comprising \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine derived\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    constant domains\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," and variable domains derived from a known \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    anti-NGF antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," such as \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    alphaD11\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," could not be guaranteed to bind to \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",". Furthermore, such an \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    antibody\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," may exhibit cross-reactivity to other target epitopes which may be present in canines, but not present in the species from which the antibody was originally derived. Furthermore, the production of neutralising antibodies would limit the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    long term therapeutic administration\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," of the antibody, this being a particularly important requirement when treating a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    chronic pain related condition\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," or a \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    cancerous condition\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",". Likewise, the production of a caninised form of an anti-NGF antibody using \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    CDR grafting\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n",", or a related technique may also result in neutralising antibody production and may further exhibit a reduction in \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    antigen binding affinity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," and avidity. Accordingly, there is a serious need for \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding members\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," which act as antagonists of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    canine NGF\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," for use in pain management in canines, wherein the \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding members\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," retain high levels of \n","<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n","    binding affinity\n","    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Diagnostic_procedure</span>\n","</mark>\n"," and avidity, while avoiding the production of neutralising antibodies there against.</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"},{"data":{"text/html":["<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Summary of the invention</div></span>"],"text/plain":["<IPython.core.display.HTML object>"]},"metadata":{},"output_type":"display_data"}],"source":["import spacy\n","c07k=open('./C07K.txt').read().strip()\n","patent_lines = c07k.split('\\n')\n","\n","nlp_ner = spacy.load(\"./NER_model/model-best\")\n","\n","colors = {\"TECH\": \"#7DF6D9\", \"MEDICALCONDITION\":\"#FFFFFF\"}\n","options = {\"colors\": colors} \n","\n","for line in patent_lines[10000:10010]:\n","    doc = nlp_ner(line)\n","    spacy.displacy.render(doc, style=\"ent\", options= options, jupyter=True)"]}],"metadata":{"kernelspec":{"display_name":"Python 3","language":"python","name":"python3"},"language_info":{"codemirror_mode":{"name":"ipython","version":3},"file_extension":".py","mimetype":"text/x-python","name":"python","nbconvert_exporter":"python","pygments_lexer":"ipython3","version":"3.10.8"}},"nbformat":4,"nbformat_minor":4}
